Advertisement
Research Article| Volume 202, P126-130, January 01, 2016

Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction

  • Author Footnotes
    1 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
    Ahmed S. Abdelmoneim
    Footnotes
    1 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
    Affiliations
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.

    Alliance for Canadian Health Outcomes Research in Diabetes, University of Alberta, Edmonton, AB, Canada
    Search for articles by this author
  • Author Footnotes
    1 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
    Robert C. Welsh
    Footnotes
    1 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
    Affiliations
    Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
    Search for articles by this author
  • Author Footnotes
    1 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
    Dean T. Eurich
    Footnotes
    1 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
    Affiliations
    Alliance for Canadian Health Outcomes Research in Diabetes, University of Alberta, Edmonton, AB, Canada

    Department of Public Health Sciences, School of Public Health, University of Alberta, Edmonton, AB, Canada
    Search for articles by this author
  • Author Footnotes
    1 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
    Scot H. Simpson
    Correspondence
    Corresponding author at: Faculty of Pharmacy & Pharmaceutical Sciences, 3-171 Edmonton Clinic Health Academy, University of Alberta, 11405-87 Ave., Edmonton, AB T6G 1C9, Canada.
    Footnotes
    1 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
    Affiliations
    Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, Canada.

    Alliance for Canadian Health Outcomes Research in Diabetes, University of Alberta, Edmonton, AB, Canada
    Search for articles by this author
  • Author Footnotes
    1 This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.
Published:August 31, 2015DOI:https://doi.org/10.1016/j.ijcard.2015.08.213
Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction
Previous ArticleThe vital role the ductus arteriosus plays in the fetal diagnosis of congenital heart disease: Evaluation by fetal echocardiography in combination with an innovative cardiovascular cast technology
Next ArticleRepeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis

      Abstract

      Background

      Animal models have demonstrated that sulfonylureas increase the size of myocardial infarction; however, data in humans is scarce. This study evaluated the association between sulfonylurea use and infarct size in diabetes patients with ST-elevation myocardial infarction (STEMI).

      Methods

      Consecutive STEMI patients admitted in Edmonton, Canada between 2006 and 2011 were enrolled in a regional prospective registry program. Patients with type 2 diabetes were identified from this group and the maximum recorded troponin I (max cTnI) within the first 48 h of chest pain onset was used as the primary outcome to quantify infarct size. The relationship between preadmission sulfonylurea use and max cTnI was assessed using multivariable linear regression to adjust for patient demographics, cardiovascular risk factors, clinical data on admission, ischemia time, reperfusion therapy and preadmission drugs.

      Results

      There were 560 STEMI patients with type 2 diabetes; mean (standard deviation; SD) age was 63.3 (12.8) years, 395 (70.5%) were male, 216 (38.6%) received primary percutaneous intervention, and 211 (37.7%) received thrombolysis. The max cTnI was higher in 146 sulfonylurea users compared to 414 non-sulfonylurea users (mean (SD): 49.8 (74.3) ng/mL versus 39.9 (50.4) ng/mL, respectively; adjusted between-group difference: 12.9 ng/mL; 95% CI 0.3–25.5; p = 0.044).

      Conclusion

      This study adds further evidence to the proposed causal relationship between sulfonylureas and adverse cardiovascular events by observing a significant difference in infarct size among type 2 diabetes patients presenting with STEMI. Clinicians should consider this association when prescribing sulfonylureas to manage patients with type 2 diabetes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Booth G.L.
        • Kapral M.K.
        • Fung K.
        • Tu J.V.
        Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study.
        Lancet. 2006; 368: 29-36
        View in Article
        • Haffner S.M.
        • Lehto S.
        • Rönnemaa T.
        • Pyorala K.
        • Laakso M.
        Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
        N. Engl. J. Med. 1998; 339: 229-234
        View in Article
        • Kannel W.B.
        • McGee D.L.
        Diabetes and cardiovascular disease. The Framingham study.
        JAMA. 1979; 241: 2035-2038
        View in Article
        • Van Dieren S.
        • Beulens J.W.J.
        • van der Schouw Y.T.
        • Grobbee D.E.
        • Neal B.
        The global burden of diabetes and its complications: an emerging pandemic.
        Eur. J. Cardiovasc. Prev. Rehabil. 2010; 17: S3-S8
        View in Article
        • Nissen S.E.
        Cardiovascular effects of diabetes drugs: emerging from the dark ages.
        Ann. Intern. Med. 2012; 157: 671-672
        View in Article
        • Nissen S.E.
        • Wolski K.
        Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.
        Arch. Intern. Med. 2010; 170: 1191-1201
        View in Article
        • Nissen S.E.
        • Wolski K.
        Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
        NEJM. 2007; 356: 2457-2471
        View in Article
        • Meinert C.L.
        • Knatterud G.L.
        • Prout T.E.
        • Klimt C.R.
        A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.
        Diabetes. 1970; 19: 789-830
        View in Article
        • UK Prospective Diabetes Study (UKPDS) Group
        Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
        Lancet. 1998; 352: 837-853
        View in Article
        • Abdelmoneim A.S.
        • Eurich D.T.
        • Light P.E.
        • Senior P.A.
        • Seubert J.M.
        • Makowsky M.J.
        • et al.
        Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.
        Diabetes Obes. Metab. 2015; 17: 523-532
        View in Article
        • Vaccaro O.
        • Masulli M.
        • Bonora E.
        • Del Prato S.
        • Giorda C.B.
        • Maggioni A.P.
        • et al.
        Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
        Nutr. Metab. Cardiovasc. Dis. 2012; 22: 997-1006
        View in Article
        • Rosenstock J.
        • Marx N.
        • Kahn S.E.
        • Zinman B.
        • Kastelein J.J.
        • Lachin J.M.
        • et al.
        Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial.
        Diab. Vasc. Dis. Res. 2013; 10: 289-301
        View in Article
        • Moheet A.
        • Seaquist E.R.
        Hypoglycemia as a driver of cardiovascular risk in diabetes.
        Curr. Atheroscler. Rep. 2013; 15: 351
        View in Article
        • Nordin C.
        The proarrhythmic effect of hypoglycemia: evidence for increased risk from ischemia and bradycardia.
        Acta Diabetol. 2014; 51: 5-14
        View in Article
        • Meier J.J.
        • Gallwitz B.
        • Schmidt W.E.
        • Mugge A.
        • Nauck M.A.
        Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?.
        Heart. 2004; 90: 9-12
        View in Article
        • Murry C.E.
        • Jennings R.B.
        • Reimer K.A.
        Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.
        Circulation. 1986; 74: 1124-1136
        View in Article
        • Kristiansen S.B.
        • Løfgren B.
        • Nielsen J.M.
        • Stottrup N.B.
        • Buhl E.S.
        • Nielsen-Kudsk J.E.
        • et al.
        Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetes.
        Diabetologia. 2011; 54: 451-458
        View in Article
        • Nieszner E.
        • Posa I.
        • Kocsis E.
        • Pogatsa G.
        • Preda I.
        • Koltai M.Z.
        Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.
        Exp. Clin. Endocrinol. Diabetes. 2002; 110: 212-218
        View in Article
        • Kottenberg E.
        • Thielmann M.
        • Kleinbongard P.
        • Frey U.H.
        • Heine T.
        • Jakob H.
        • et al.
        Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation.
        Acta Anaesthesiol. Scand. 2014; 58: 453-462
        View in Article
        • Klamann A.
        • Sarfert P.
        • Launhardt V.
        • Schulte G.
        • Schmiegel W.H.
        • Nauck M.A.
        Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide).
        Eur. Heart J. 2000; 21: 220-229
        View in Article
        • Horsdal H.T.
        • Johnsen S.P.
        • Søndergaard F.
        • Rungby J.
        Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study.
        Diabetologia. 2008; 51: 567-574
        View in Article
        • Bainey K.R.
        • Ferguson C.
        • Ibrahim Q.I.
        • Tyrrell B.
        • Welsh R.C.
        Impact of reperfusion strategy on aborted myocardial infarction: insights from a large Canadian ST-Elevation Myocardial Infarction Clinical Registry.
        Can. J. Cardiol. 2014; 30: 1570-1575
        View in Article
        • Adams J.E.
        • Bodor G.S.
        • Dávila-Román V.G.
        • Delmez J.A.
        • Apple F.S.
        • Ladenson J.H.
        • et al.
        Cardiac troponin I. A marker with high specificity for cardiac injury.
        Circulation. 1993; 88: 101-106
        View in Article
        • Chia S.
        • Senatore F.
        • Raffel O.C.
        • Lee H.
        • Wackers F.J.
        • Jang I.K.
        Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
        JACC Cardiovasc. Interv. 2008; 1: 415-423
        View in Article
        • Hallén J.
        • Buser P.
        • Schwitter J.
        • Petzelbauer P.
        • Geudelin B.
        • Fagerland M.W.
        • et al.
        Relation of cardiac troponin I measurements at 24 and 48 hours to magnetic resonance-determined infarct size in patients with ST-elevation myocardial infarction.
        Am. J. Cardiol. 2009; 104: 1472-1477
        View in Article
        • Vasile V.C.
        • Babuin L.
        • Giannitsis E.
        • Katus H.A.
        • Jaffe A.S.
        Relationship of MRI-determined infarct size and cTnI measurements in patients with ST-elevation myocardial infarction.
        Clin. Chem. 2008; 54: 617-619
        View in Article
        • Di Chiara A.
        • Dall'Armellina E.
        • Badano L.P.
        • Meduri S.
        • Pezzutto N.
        • Fioretti P.M.
        Predictive value of cardiac troponin-I compared to creatine kinase-myocardial band for the assessment of infarct size as measured by cardiac magnetic resonance.
        J. Cardiovasc. Med. (Hagerstown). 2010; 11: 587-592
        View in Article
        • Shariff N.
        • Dunbar C.
        • Matsumura M.E.
        Relation of pre-event use of inhibitors of the renin–angiotensin system with myocardial infarct size in patients presenting with a first ST-segment elevation myocardial infarction.
        Am. J. Cardiol. 2010; 106: 646-649
        View in Article
        • Moran L.
        • Fugate T.
        • Xiang Y.
        • Cianci C.
        • Matsumura M.
        Statin pretreatment is protective despite an association with greater coronary artery disease burden in patients presenting with a first ST-elevation myocardial infarction.
        Prev. Cardiol. 2008; 11: 21-25
        View in Article
        • Lexis C.P.H.
        • Wieringa W.G.
        • Hiemstra B.
        • van Deursen V.M.
        • Lipsic E.
        • van der Harst P.
        • et al.
        Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction.
        Cardiovasc. Drugs Ther. 2014; 28: 163-171
        View in Article
        • Schafer J.
        Multiple imputation: a primer.
        Stat. Methods Med. Res. 1999; 8: 3-15
        View in Article
        • Toombs C.F.
        • Moore T.L.
        • Shebuski R.J.
        Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide.
        Cardiovasc. Res. 1993; 27: 617-622
        View in Article
        • Mitani A.
        • Kinoshita K.
        • Fukamachi K.
        • Sakamoto M.
        • Kurisu K.
        • Tsuruhara Y.
        • et al.
        Effects of glibenclamide and nicorandil on cardiac function during ischemia and reperfusion in isolated perfused rat hearts.
        Am. J. Physiol. 1991; 261: H1864-H1871
        View in Article
        • Maddock H.L.
        • Siedlecka S.M.
        • Yellon D.M.
        Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide.
        Cardiovasc. Drugs Ther. 2004; 18: 113-119
        View in Article
        • Samaha F.F.
        • Heineman F.W.
        • Ince C.
        • Fleming J.
        • Balaban R.S.
        ATP-sensitive potassium channel is essential to maintain basal coronary vascular tone in vivo.
        Am. J. Physiol. 1992; 262: C1220-C1227
        View in Article
        • Imamura Y.
        • Tomoike H.
        • Narishige T.
        • Takahashi T.
        • Kasuya H.
        • Takeshita A.
        Glibenclamide decreases basal coronary blood flow in anesthetized dogs.
        Am. J. Physiol. 1992; 263: H399-H404
        View in Article
        • Singh T.P.
        • Nigam A.K.
        • Gupta A.K.
        • Singh B.
        Cardiac biomarkers: when to test? — physician perspective.
        J. Ind. Acad. Clin. Med. 2011; 12: 117-121
        View in Article
        • Danchin N.
        • Charpentier G.
        • Ledru F.
        • Vaur L.
        • Gueret P.
        • Hanania G.
        • et al.
        Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry.
        Diabetes Metab. Res. Rev. 2005; 21: 143-149
        View in Article
        • Zeller M.
        • Danchin N.
        • Simon D.
        • Vahanian A.
        • Lorgis L.
        • Cottin Y.
        • et al.
        Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.
        J. Clin. Endocrinol. Metab. 2010; 95: 4993-5002
        View in Article
        • Halkin A.
        • Roth A.
        • Jonas M.
        • Behar S.
        Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction.
        J. Thromb. Thrombolysis. 2001; 12: 177-184
        View in Article
        • Wright R.J.
        • Frier B.M.
        Vascular disease and diabetes: is hypoglycaemia an aggravating factor?.
        Diabetes Metab Res Rev. 2008; 24: 353-363
        View in Article
        • Corley B.T.
        • Davenport C.
        • Delaney L.
        • Hatunic M.
        • Smith D.
        Hypoglycaemia-induced myocardial infarction as a result of sulphonylurea misuse.
        Diabet. Med. 2011; 28: 876-879
        View in Article
        • Ashcroft F.M.
        • Rorsman P.
        Electrophysiology of the pancreatic beta-cell.
        Prog. Biophys. Mol. Biol. 1989; 54: 87-143
        View in Article
        • Gribble F.M.
        • Ashcroft F.M.
        Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues.
        Metabolism. 2000; 49: 3-6
        View in Article
        • Nichols C.G.
        • Singh G.K.
        • Grange D.K.
        KATP channels and cardiovascular disease: suddenly a syndrome.
        Circ. Res. 2013; 112: 1059-1072
        View in Article
        • Gribble F.M.
        • Reimann F.
        Sulphonylurea action revisited: the post-cloning era.
        Diabetologia. 2003; 46: 875-891
        View in Article
        • Li R.A.
        • Leppo M.
        • Miki T.
        • Seino S.
        • Marban E.
        Molecular basis of electrocardiographic ST-segment elevation.
        Circ. Res. 2000; 87: 837-839
        View in Article
        • Huizar J.F.
        • Gonzalez L.A.
        • Alderman J.
        • Smith H.S.
        Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics.
        J. Am. Coll. Cardiol. 2003; 42: 1017-1021
        View in Article
        • Hausenloy D.J.
        • Wynne a.M.
        • Mocanu M.M.
        • Yellon D.M.
        Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart.
        J. Cardiovasc. Pharmacol. Ther. 2012; 18: 263-269
        View in Article

      Article info

      Publication history

      Published online: August 31, 2015
      Accepted: August 27, 2015
      Received: June 19, 2015

      Identification

      DOI: https://doi.org/10.1016/j.ijcard.2015.08.213

      Copyright

      © 2015 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX